Catherine Lindgren

3.9k total citations · 3 hit papers
40 papers, 2.9k citations indexed

About

Catherine Lindgren is a scholar working on Oncology, Immunology and Hematology. According to data from OpenAlex, Catherine Lindgren has authored 40 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 21 papers in Immunology and 7 papers in Hematology. Recurrent topics in Catherine Lindgren's work include CAR-T cell therapy research (25 papers), Immune Cell Function and Interaction (14 papers) and Immunotherapy and Immune Responses (10 papers). Catherine Lindgren is often cited by papers focused on CAR-T cell therapy research (25 papers), Immune Cell Function and Interaction (14 papers) and Immunotherapy and Immune Responses (10 papers). Catherine Lindgren collaborates with scholars based in United States, Switzerland and Canada. Catherine Lindgren's co-authors include Michael C. Jensen, Stanley R. Riddell, Oliver W. Press, Philip D. Greenberg, Andrew Raubitschek, Jinjuan Wang, Stephen J. Forman, Xiaojun Qian, Brian G. Till and Julie R. Park and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

Catherine Lindgren

40 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults

2017 787 citations Rebecca Gardner, Olivia Finney et al. Blood profile →
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells

2008 573 citations Brian G. Till, Michael C. Jensen et al. Blood profile →
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results

2012 431 citations Brian G. Till, Michael C. Jensen et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Catherine Lindgren United States	19	2.5k	1.1k	801	691	643	40	2.9k
Antonio Di Stasi United States	16	2.2k 0.9×	954 0.9×	916 1.1×	887 1.3×	648 1.0×	42	2.8k
D. Stroncek United States	5	2.1k 0.8×	665 0.6×	652 0.8×	580 0.8×	556 0.9×	12	2.3k
Cindy Delbrook United States	16	2.9k 1.2×	792 0.7×	880 1.1×	760 1.1×	715 1.1×	27	3.3k
Bianca Santomasso United States	19	3.2k 1.3×	764 0.7×	683 0.9×	779 1.1×	653 1.0×	46	3.7k
Nicholas Tschernia United States	7	2.1k 0.8×	614 0.6×	656 0.8×	590 0.9×	558 0.9×	20	2.3k
Chihaya Imai Japan	17	2.1k 0.8×	1.6k 1.5×	515 0.6×	578 0.8×	409 0.6×	69	2.8k
Barbara Camisa Italy	13	1.8k 0.7×	1.2k 1.1×	533 0.7×	598 0.9×	518 0.8×	27	2.6k
Rebecca Gardner United States	13	1.8k 0.7×	446 0.4×	592 0.7×	514 0.7×	504 0.8×	23	2.1k
Maksim Mamonkin United States	19	1.8k 0.7×	746 0.7×	691 0.9×	738 1.1×	377 0.6×	59	2.1k

Countries citing papers authored by Catherine Lindgren

Since Specialization

Citations

This map shows the geographic impact of Catherine Lindgren's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Catherine Lindgren with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Catherine Lindgren more than expected).

Fields of papers citing papers by Catherine Lindgren

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Catherine Lindgren. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Catherine Lindgren. The network helps show where Catherine Lindgren may publish in the future.

Co-authorship network of co-authors of Catherine Lindgren

This figure shows the co-authorship network connecting the top 25 collaborators of Catherine Lindgren. A scholar is included among the top collaborators of Catherine Lindgren based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Catherine Lindgren. Catherine Lindgren is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Annesley, Colleen, Kristy Seidel, Qian Wu, et al.. (2025). Outcomes of PLAT-02 and PLAT-03: Evaluating CD19 CAR T-Cell Therapy and CD19-expressing T-APC Support in Pediatric B-ALL. Blood. 146(7). 789–801. 2 indexed citations

Annesley, Colleen, Adam J. Lamble, Corinne Summers, et al.. (2024). Feasibility and favorable responses after investigational CAR T-cell therapy for relapsed and refractory infant ALL. Blood Advances. 9(9). 2068–2078. 2 indexed citations

Ceppi, Francesco, Ashley Wilson, Colleen Annesley, et al.. (2022). Modified Manufacturing Process Modulates CD19CAR T-cell Engraftment Fitness and Leukemia-Free Survival in Pediatric and Young Adult Subjects. Cancer Immunology Research. 10(7). 856–870. 14 indexed citations

Cooper, Todd M., Vicky Wu, Ashley Wilson, et al.. (2022). Pediatric and young adult leukemia adoptive therapy (PLAT)-08: A phase 1 study of SC-DARIC33 in pediatric and young adults with relapsed or refractory CD33+ AML.. Journal of Clinical Oncology. 40(16_suppl). TPS7078–TPS7078. 6 indexed citations

Annesley, Colleen, Corinne Summers, Michael A. Pulsipher, et al.. (2021). SCRI-CAR19x22v2 T Cell Product Demonstrates Bispecific Activity in B-ALL. Blood. 138(Supplement 1). 470–470. 16 indexed citations

Gardner, Rebecca, Colleen Annesley, Ashley Wilson, et al.. (2020). Efficacy of SCRI-CAR19x22 T cell product in B-ALL and persistence of anti-CD22 activity.. Journal of Clinical Oncology. 38(15_suppl). 3035–3035. 10 indexed citations

Ceppi, Francesco, Julie Rivers, Colleen Annesley, et al.. (2018). Lymphocyte apheresis for chimeric antigen receptor T‐cell manufacturing in children and young adults with leukemia and neuroblastoma. Transfusion. 58(6). 1414–1420. 71 indexed citations

Gardner, Rebecca, Olivia Finney, Hannah Smithers, et al.. (2016). CD19CAR T Cell Products of Defined CD4:CD8 Composition and Transgene Expression Show Prolonged Persistence and Durable MRD-Negative Remission in Pediatric and Young Adult B-Cell ALL. Blood. 128(22). 219–219. 31 indexed citations

Till, Brian G., Michael C. Jensen, Jinjuan Wang, et al.. (2012). CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood. 119(17). 3940–3950. 431 indexed citations breakdown →

10.

Till, Brian G., Michael C. Jensen, Jinjuan Wang, et al.. (2008). Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood. 112(6). 2261–2271. 573 indexed citations breakdown →

11.

Wang, Jinjuan, Michael C. Jensen, Yukang Lin, et al.. (2007). Optimizing Adoptive Polyclonal T Cell Immunotherapy of Lymphomas, Using a Chimeric T Cell Receptor Possessing CD28 and CD137 Costimulatory Domains. Human Gene Therapy. 18(8). 712–725. 177 indexed citations

12.

Wang, Jinjuan, Oliver W. Press, Catherine Lindgren, et al.. (2004). Cellular Immunotherapy for Follicular Lymphoma Using Genetically Modified CD20-Specific CD8+ Cytotoxic T Lymphocytes. Molecular Therapy. 9(4). 577–586. 73 indexed citations

13.

Petersdorf, Stephen H., Oliver W. Press, Catherine Lindgren, et al.. (1997). Interleukin-2 after autologous stem cell transplantation for hematologic malignancy: a phase I/II study. Bone Marrow Transplantation. 19(5). 435–442. 33 indexed citations

14.

Fefer, Alexander, Mark Benyunes, William Bensinger, et al.. (1997). Interleukin-2 therapy after bone marrow or stem cell transplantation for hematologic malignancies.. PubMed. 3 Suppl 1. S48–53. 16 indexed citations

15.

Benyunes, Mark, Carl M. Higuchi, Catherine Lindgren, et al.. (1995). Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial.. PubMed. 16(2). 283–8. 53 indexed citations

16.

Fefer, A, et al.. (1993). lnterleukin-2 ± Lymphocytes as Consolidative Immunotherapy after Autologous Bone Marrow Transplantation for Hematologic Malignancies. Acta Haematologica. 89(1). 2–7. 19 indexed citations

17.

Lindgren, Catherine, John A. Thompson, Carl M. Higuchi, & Alexander Fefer. (1993). Growth and Autologous Tumor Lysis by Tumor-Infiltrating Lymphocytes from Metastatic Melanoma Expanded in Interleukin-2 or Interleukin-2 plus Interleukin-4. Journal of Immunotherapy. 14(4). 322–328. 4 indexed citations

18.

Thompson, John A., Catherine Lindgren, Mark Benyunes, et al.. (1993). The Effects of Pentoxifylline on the Generation of Human Lymphokine-Activated Killer Cell Cytotoxicity. Journal of Immunotherapy. 13(2). 84–90. 4 indexed citations

19.

Thompson, John A., Keith L. Shulman, Mark Benyunes, et al.. (1992). Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma.. Journal of Clinical Oncology. 10(6). 960–968. 53 indexed citations

20.

Thompson, John A., Catherine Lindgren, C. B. Collins, et al.. (1989). Influence of schedule of interleukin 2 administration on therapy with interleukin 2 and lymphokine activated killer cells.. PubMed. 49(1). 235–40. 63 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact